(Q61628446)
Statements
UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug (English)
0 references
Adrian Kielhorn
Alexander Diamantopoulos
6 August 2008
0 references